Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Century Therapeutics, Inc. (IPSC)

10.2   -0.05 (-0.49%) 12-06 09:42
Open: 10.72 Pre. Close: 10.25
High: 10.28 Low: 9.92
Volume: 4,409 Market Cap: 602(M)

Technical analysis

as of: 2022-12-06 9:19:41 AM
Overall:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 12.96     One year: 13.95
Support: Support1: 9.72    Support2: 8.08
Resistance: Resistance1: 11.09    Resistance2: 11.94
Pivot: 10.52
Moving Average: MA(5): 10.5     MA(20): 10.55
MA(100): 10.55     MA(250): 11.25
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 41.3     %D(3): 38.8
RSI: RSI(14): 47.1
52-week: High: 19.38  Low: 7.32
Average Vol(K): 3-Month: 86 (K)  10-Days: 46 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IPSC ] has closed above bottom band by 23.1%. Bollinger Bands are 49.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.81 - 10.86 10.86 - 10.9
Low: 9.91 - 9.96 9.96 - 10.01
Close: 10.16 - 10.26 10.26 - 10.33

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Mon, 05 Dec 2022
2022 IPSC World Shoot: Luke Cao Wins Production Optics Light Division | An NRA Shooting Sports Journal - Shooting Sports USA

Mon, 05 Dec 2022
SHORELINE BIOSCIENCES ANNOUNCES ORAL PRESENTATION ON NOVEL MANUFACTURING METHOD OF INK CELLS AT THE 64TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) 2022 MEETING - PR Newswire

Sat, 03 Dec 2022
PH team finishes 2nd in IPSC World Shoot - pna.gov.ph

Mon, 28 Nov 2022
Induced Pluripotent Stem Cell (iPSC) Global Market to Reach $3.99 Billion by 2026 at a 10.5% CAGR - PR Newswire

Mon, 28 Nov 2022
Using human iPSC-derived cells to revolutionize the field of neurodegenerative disease - News-Medical.Net

Sat, 26 Nov 2022
Results: 2022 IPSC Pan-American Handgun Championship | An NRA Shooting Sports Journal - Shooting Sports USA

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 59 (M)
% Held by Insiders 2.136e+007 (%)
% Held by Institutions 36.5 (%)
Shares Short 2,230 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.1184e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 533
Return on Equity (ttm) -15.1
Qtrly Rev. Growth 4.68e+006
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.67
Qtrly Earnings Growth 0.1
Operating Cash Flow 0 (M)
Levered Free Cash Flow 13 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0.2
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 2.18e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.